RWTH Aachen University
rwth-aachen.deTotal trials
230
Active
18
Phase 3
18
Total enrollment
100,272,480
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ruxolitinib | — | — | — | — | — | 1 | |
| BAT | — | — | — | — | — | 1 | |
| Pentaglobin®/Standard of Care | — | — | — | — | — | 1 | |
| Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism | — | — | — | — | — | 1 | |
| Genotyping | — | — | — | — | — | 1 |
Next readouts
- 2027-09
- 2027-12
- 2028-12
- 2032-02
Top conditions
- COPD6
- Heart Failure5
- Asthma4
- Diaphragm Injury3
- Schizophrenia3
- Diabetes Mellitus Type 2 (T2DM)3
- Chronic Kidney Disease3
- Acute Coronary Syndrome3
Frequently asked questions about RWTH Aachen University
- How many clinical trials does RWTH Aachen University have on ClinicalTrials.gov?
- RWTH Aachen University is listed as the lead sponsor on 230 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of RWTH Aachen University's trials are in Phase 3?
- 18 of RWTH Aachen University's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does RWTH Aachen University focus on?
- RWTH Aachen University's most-studied conditions on ClinicalTrials.gov are COPD, Heart Failure, Asthma, Diaphragm Injury, Schizophrenia.
- When are RWTH Aachen University's next clinical trial readouts?
- RWTH Aachen University has 4 upcoming primary-completion readouts tracked here; the soonest is “Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis”, expected around 2027-09.